![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Preview
Status quo obviously is not optimal in the management of patients with non-insulin-dependent diabetes, given the fact that the average hemoglobin A1c value in this diabetic population is between 9% and 10%. There is an impetus, therefore, to move up the treatment ladder more quickly than at present. The availability of new oral hypoglycemic agents provides the potential for expanding the role of this category of agents and for improving overall glycemic control in these patients.
Additional information
Notes on contributors
Priscilla A. Hollander
Priscilla A. Hollander, MD, PhD Dr Hollander is a member of the division of endocrinology and diabetes and is vice president for adult diabetes and special studies, International Diabetes Center, Park Nicollet Medical Center, Minneapolis.